Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to
Melissa A Tran1, Charles D Smith, Mark Kester
1Department of Pharmacology-R130, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
Summary
Combining sorafenib with nanoliposomal ceramide synergistically inhibits cancer cells by targeting key signaling pathways. This combination therapy shows enhanced tumor inhibition with increased apoptosis and reduced proliferation, establishing a basis for clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Aberrant phosphatidylinositol 3-kinase/Akt and Ras/Raf/MAPK pathways drive melanoma and breast cancer progression.
- Simultaneous targeting of these pathways offers a potential strategy for synergistic tumor inhibition.
- Identifying agents with manageable toxicity and a clear mechanistic basis for synergy is crucial.
Purpose of the Study:
- To evaluate the preclinical therapeutic efficacy of combining sorafenib with nanoliposomal ceramide.
- To assess the associated toxicity of this combination therapy.
- To elucidate the mechanistic basis for synergistic effects.
Main Methods:
- Cellular assays (MTT) and CalcuSyn software assessed synergistic inhibition.
- Western blotting analyzed cooperative effects on signaling pathways (MAPK, PI3K/Akt).
- In vivo studies measured tumor growth, apoptosis, and angiogenesis; toxicity was assessed via animal weight, blood parameters, and liver histology.
Main Results:
- Sorafenib and nanoliposomal ceramide demonstrated synergistic inhibition of cancer cells.
- Combination therapy significantly increased apoptosis (1-2 fold) and decreased proliferation (3-4 fold) compared to single agents.
- In vivo, the combination achieved ~30% greater tumor inhibition than sorafenib alone and ~58% tumor size reduction versus nanoliposomal ceramide, with doubled apoptosis rates and minimal toxicity.
Conclusions:
- Nanoliposomal ceramide enhances sorafenib's effectiveness, leading to synergistic anti-cancer activity.
- The combination therapy shows promising preclinical results with manageable toxicity.
- This study provides a foundation for clinical trials investigating sorafenib and nanoliposomal ceramide in cancer treatment.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.